Vyant Bio
VYNT
VYNT was delisted on the 12th of May, 2023.
32 hedge funds and large institutions have $10.4M invested in Vyant Bio in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 7 closing their positions.
211% more capital inflows, than outflows
Capital inflows: $1.38M | Capital outflows: $445K
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
10% more funds holding
Funds holding: 29 → 32 (+3)
1.68% more ownership
Funds ownership: 11.7% → 13.37% (+1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$330K |
| 2 |
EAM Investors
Solana Beach,
California
|
+$280K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$223K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$95.7K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$69.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$181K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$97K |
| 3 |
Perkins Capital Management
Wayzata,
Minnesota
|
-$63.3K |
| 4 |
Squarepoint
New York
|
-$42K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$25K |
VYNT Hedge Fund Activity: Q1 2017 in Review
32 of the 4,036 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio (VYNT) for Q1 2017, worth a combined $10.4M — up 248% from $2.98M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new VYNT positions and 7 closed out — a net gain of 4 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $330K. The largest seller was Jacobs Levy Equity Management, cutting an estimated $181K.
- 32 institutional investors held Vyant Bio (VYNT) as of Q1 2017, up from 29 in Q4 2016.
- Funds reported $10.4M of Vyant Bio stock for Q1 2017, up 248% quarter-over-quarter.
- 11 funds opened new Vyant Bio positions in Q1 2017 and 7 closed out, a net change of +4 holders.
- The largest Vyant Bio buyer in Q1 2017 was Renaissance Technologies, an estimated $330K added.
- The largest Vyant Bio seller in Q1 2017 was Jacobs Levy Equity Management, an estimated $181K sold.
Based on aggregated 13F filings for Q1 2017.